Safety evaluation of perioperative maintenance antiplatelet therapy in transurethral plasmakinetic enucle-ation of the prostate
Objective To evaluate the safety of perioperative maintenance of aspirin antiplatelet therapy in patients under-going transurethral plasmakinetic enucleation of the prostate.Methods 85 patients with benign prostatic hyperplasia who under-went transurethral plasma enucleation of the prostate in the Department of Urology,Lianyungang Hospital of traditional Chinese medi-cine from January 2017 to December 2023 were retrospectively analyzed.They were divided into aspirin group(perioperative mainte-nance of aspirin antiplatelet therapy,n=37),the control group(aspirin was stopped one week before surgery,and aspirin antiplatelet therapy was taken again one week after surgery,n=48).The surgical time,volume of resected prostate,surgical blood loss,bladder flushing time,International Prostate Symptom Score(IPSS score),bladder residual urine volume(BVR)and maximum urine flow(Qmax)were compared between the two groups.Results There was no significant difference in surgical time,volume of resected pros-tate,blood loss and bladder flushing time between the two groups(P>0.05).There was no significant difference in IPSS,BVR and Qmax be-tween the two groups(P>0.05).There were no cases of blood transfu-sion or unexpected secondary surgery,and no cardiovascular events or other complications in the two groups.The IPSS,BVR and Qmax of the two groups were significantly improved 3 months after the surgery compared with those before the surgery(P<0.05),but there was no significant difference between the aspirin group and the control group(P>0.05).Conclusion It is safe and effective to maintain as-pirin antiplatelet therapy in patients undergoing transurethral plasmakinetic enucleation of the prostate during the perioperative period,without increasing the risk of perioperative bleeding or other complications.
transurethral plasmakinetic enucleation of prostateantiplatelet therapyaspirinbenign prostatic hyperplasia